Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer

Research output: Contribution to journalReview articlepeer-review

Abstract

Interest in precision diagnostics has been fuelled by the concept that early detection of cancer would benefit patients; that is, if detected early, more tumours should be resectable and treatment more efficacious. Serum contains massive amounts of potentially diagnostic information, and affinity proteomics has risen as an accurate approach to decipher this, to generate actionable information that should result in more precise and evidence-based options to manage cancer. To achieve this, we need to move from single to multiplex biomarkers, a so-called signature, that can provide significantly increased diagnostic accuracy. This Opinion article focuses on the progress being made in identifying protein biomarker signatures of clinical utility, using blood-based proteomics.

Original languageEnglish
Pages (from-to)199-204
JournalNature Reviews Cancer
Volume17
Issue number3
DOIs
Publication statusPublished - 2017

Subject classification (UKÄ)

  • Immunology in the medical area

Fingerprint

Dive into the research topics of 'Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer'. Together they form a unique fingerprint.

Cite this